A phase 1 trial of RCT2100 in Cystic Fibrosis patients
Latest Information Update: 22 Feb 2024
At a glance
- Drugs RCT 2100 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
Most Recent Events
- 22 Feb 2024 New trial record
- 21 Feb 2024 According to a ReCode Therapeutics media release, company plans to submit an Investigational New Drug application (IND) to the U.S. Food and Drug Administration for a Phase 1 trial of RCT2100 in CF patients in the first half of 2024.